Trevena Stock (NASDAQ:TRVN)


ForecastRevenueFinancialsChartTranscripts

Previous Close

$1.70

52W Range

$1.13 - $19.23

50D Avg

$2.98

200D Avg

$7.61

Market Cap

$1.47M

Avg Vol (3M)

$36.46K

Beta

1.02

Div Yield

-

TRVN Company Profile


Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

23

IPO Date

Jan 31, 2014

Website

TRVN Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
License revenue$3.00M$20.00K$69.00K
License and royalty revenues$3.18M--
Royalty revenue$179.00K--
Product revenue--$498.00K

Fiscal year ends in Dec 23 | Currency in USD

TRVN Financial Summary


Dec 23Dec 22Dec 21
Revenue$3.13M$-418.00K$567.00K
Operating Income$-35.29M$-56.38M$-51.92M
Net Income$-40.29M$-53.67M$-51.16M
EBITDA$-34.40M$-56.38M$-51.92M
Basic EPS$-3.16$-7.59$-7.84
Diluted EPS$-3.16$-7.59$-7.84

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 23Nov 14, 23 | 9:21 AM
Q1 23May 15, 23 | 9:21 AM
Q4 22Mar 31, 23 | 3:07 PM

Peer Comparison


TickerCompany
NBRVNabriva Therapeutics plc
VSTMVerastem, Inc.
ACRXTalphera, Inc.
VTVTvTv Therapeutics Inc.
LPCNLipocine Inc.